Advise Taking "Flozins" in the Morning

October 2014

Jardiance (jar-DEE-ans, empagliflozin) will be the third SGLT2 inhibitor...after Invokana (canagliflozin) and Farxiga (dapagliflozin).

These "flozins" increase glucose excretion by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.

They all lower A1C by about 0.7% to 1%...reduce weight by 4 to 7 pounds...lower systolic BP by 3 to 5 mmHg...and rarely cause hypoglycemia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Hypertension Use Three "Core" Meds for Resistant Hypertension
Opioids Alert Patients About Changes to Their Hydrocodone Combo Rxs
Rheumatoid Arthritis Recommend Folic Acid for Rheumatoid Arthritis Patients on Methotrexate
Diabetes Advise Taking "Flozins" in the Morning
Respiratory & Allergy Save Xolair as a Last Resort for Chronic Hives
Antithrombotics Switch to Aspirin Alone After a Year for Most Stent Patients
Supplements Watch for Adverse Effects When Combining Garcinia cambogia and Serotonergic Meds
Women's Health Avoid Topical NSAIDs During Pregnancy
Cardiology Consider Starting a Beta-Blocker for Surgery in High-Risk Patients
Med Synchronization Explain "Med Sync" to Your Office Staff
Anxiety Consider Pregabalin as an Alternative to a Benzo for Anxiety
COPD Consider How Striverdi Respimat Compares to Arcapta, Foradil, or Serevent
Infectious Diseases Don't Rely on aPTT for Heparin Monitoring in Patients On Oritavancin
Substance Use Disorder Watch for Signs of Gabapentin Abuse